Form 4: NewAmsterdam Pharma Co Executive Sells Shares

Sentiment:

Insider Transaction (Form 4)


Louise Frederika Kooij, Chief Accounting Officer of NewAmsterdam Pharma Co N.V., sold 105,000 shares of common stock on July 20, 2026.

Summary

  • Option exercise/conversion: acquired 25,000 Ordinary Shares at $11.90 ($297,500) on July 20, 2026; holds 49,353 after (Direct).
  • Option exercise/conversion: acquired 80,000 Ordinary Shares at $11.17 ($893,600) on July 20, 2026; holds 129,353 after (Direct).
  • Open-market sale: disposed of 70,200 Ordinary Shares at $29.96 ($2,103,192) on July 20, 2026; holds 59,153 after (Direct).
  • Open-market sale: disposed of 31,885 Ordinary Shares at $31.05 ($990,029) on July 20, 2026; holds 27,268 after (Direct).
  • Open-market sale: disposed of 2,915 Ordinary Shares at $31.71 ($92,435) on July 20, 2026; holds 24,353 after (Direct).
  • Option exercise/conversion: disposed of 25,000 Option (right to buy) on July 20, 2026; holds 10,000 after (Direct).
  • Option exercise/conversion: disposed of 80,000 Option (right to buy) on July 20, 2026; holds 70,494 after (Direct).

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $3,185,656 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.

Insider Transactions

Louise Frederika Kooij — Officer (Chief Accounting Officer)

Transaction made under a Rule 10b5-1 trading plan.

DateTransactionSecuritySharesPriceValueHeld After
2026-07-20Option exercise/conversionOrdinary Shares25,000$12$297.5K49,353
2026-07-20Option exercise/conversionOrdinary Shares80,000$11$893.6K129,353
2026-07-20Open-market saleOrdinary Shares70,200$30$2.1M59,153
2026-07-20Open-market saleOrdinary Shares31,885$31$990.0K27,268
2026-07-20Open-market saleOrdinary Shares2,915$32$92.4K24,353
2026-07-20Option exercise/conversionOption (right to buy)25,000——10,000
2026-07-20Option exercise/conversionOption (right to buy)80,000——70,494

Key Dates

DateDescription
2026-07-20Option exercise/conversion (25,000 shares)
2026-07-20Option exercise/conversion (80,000 shares)
2026-07-20Open-market sale (70,200 shares)
2026-07-20Open-market sale (31,885 shares)
2026-07-20Open-market sale (2,915 shares)
2026-07-20Option exercise/conversion (25,000 shares)
2026-07-20Option exercise/conversion (80,000 shares)

Keywords

insider transaction, Form 4, NAMS, NewAmsterdam Pharma Co N.V., bearish, Louise Frederika Kooij

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.